Introduction
Use of beta-blockers in the perioperative setting has been questioned recently, due to concerns about their efficacy and safety, which may vary with patient subgroup. [1] [2] [3] In a non-surgical setting, several betablocker subtypes are marketed for the treatment of structural and ischaemic heart disease. Whether perioperative risks vary by subtype of beta-blocker has not been thoroughly investigated.
The risks of perioperative events may vary with beta-blocker subtype, according to adrenergic receptor selectivity (a 1-2 and b 1-3 -receptors), and the variation in specific receptors among target organs. In addition, plasma concentration and bioavailability of different beta-blockers may vary due to differences in catabolic processes in the liver and kidneys. Selecting a beta-blocker for the individual patient may therefore depend on comorbidities, treatment goals, patient preference, and available treatment alternatives.
Randomized trials with head-to-head comparisons between betablocker subtypes have previously been performed in a non-surgical setting, but due to the unique physiological stress induced by noncardiac surgery, these findings may not be extrapolated to patients undergoing surgery. 4, 5 Although many trials have evaluated specific beta-blocker subtypes against placebo including atenolol, 6, 7 bisoprolol, 8 metoprolol, [9] [10] [11] [12] and propranolol 13 , no randomized trials with head-to-head comparisons exist in a surgical setting. Few observational studies have previously compared mainly bisoprolol, atenolol, and metoprolol in a single-centre study, or in selected population of elderly patients or patients undergoing high-risk surgery. [14] [15] [16] Recent studies have suggested that the effect of beta-blocker treatment on perioperative outcomes may vary by patients cardiovascular risk and underlying comorbidities. [1] [2] [3] We conducted the current study to investigate the risks of adverse events and mortality following non-cardiac surgery in patients treated chronically with one of various beta-blocker subtypes, using a large representative cohort and clinically relevant subgroups. These results may guide clinical practice when choosing beta-blockers for patients undergoing surgery while at the same time informing investigators who are planning future trials assessing beta-blocker effects in patients undergoing non-cardiac surgery.
Methods
It was ensured that all aspects of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement was addressed. 17 This study was funded by a grant from the Lundbeck Foundation. The funding source was not involved in the organization of the study, the collection, analysis, and interpretation of the data, nor the final decision to submit this paper for publication. This was a retrospective, nationwide cohort study based on data provided by several Danish healthcare registries. Data were linked across registries by use of the unique and permanent Danish social security number assigned upon permanent residency in Denmark. Denmark has a single payer system, and all services are equally available to all permanent residents and fully tax financed, thus ensuring a wide and representative patient cohort. In agreement with Danish law and rules for reimbursement, data on diagnosis and procedures are consistently reported to the Danish National Patient Register upon hospital discharge. 18 Date and cause of death are reported to the National Population Register and the National Causes of Death Register. 19 Information on pharmacotherapy was based on out-of-hospital filled prescriptions registered in the Danish Registry for Medical Product Statistics, which have been shown to accurately represent the patients intake of medications. 20 Procedure specific variables, including surgery priority and duration of anaesthesia, were retrieved from the Danish Anesthetic Database complete since 2005. The registries have been described in further detail elsewhere. 21 
Study population
All patients undergoing non-cardiac surgery in Denmark between January 1, 2005 and December 31, 2011 were considered for this study. Please see Figure 1 for study exclusions. Patients treated with sotalol (a combined beta-blocker and antiarrhythmic drug) were excluded as this drug is used for prevention of supraventricular and ventricular tachycardia in Denmark. Chronic beta-blocker treatment was defined as a claimed prescription within 120 days of the surgery, and included patients claiming their first prescription close to surgery. However, patients with a short duration of beta blocker treatment prior to surgery (<120 days) were later analysed separately in sensitivity analyses. The first surgery for each patient within the study period was included in our analysis, while repeat surgeries within the 30-day follow-up period were excluded. Patients were grouped by use of beta-blocker subtype prior to surgery, namely atenolol, bisoprolol, carvedilol, metoprolol, propranolol, or 'other' (comprising acebutolol, nebivolol, pindolol, and labetalol). The main study cohort and four subgroups of patients (heart failure, prior myocardial infarction (MI), diabetes and uncomplicated hypertension) were analysed. Uncomplicated hypertension was defined by use of two antihypertensive drugs and the absence of cardiac-, renal-, or liver disease, as done previously, 1 (see Figure 1 for details). Table  S2 for details. 22 Use of pharmacotherapy was based on out-of-hospital claimed prescriptions within 120 days prior to surgery, see Supplementary material online, Table S3 for details. As pack size is most often < _100 tablets, 120 days were chosen to most accurately reflect patient intake of medications prior to surgery. Primary outcomes were 30-day all-cause mortality and 30-day major adverse cardiovascular events (MACE). MACE was defined as non-fatal myocardial infarction (ICD-10 I22), non-fatal ischaemic stroke (ICD-10 I63 or I64) or cardiovascular death (ICD-10 cause of death in I-category), based on hospital discharge diagnosis or cause of death. Adverse events at the day of surgery were included. The individual components of MACE were analysed as secondary outcomes.
Statistics
P-values for differences at baseline were estimated with analysis of variance and v 2 test. Missing values for body mass index were reported as a separate stratum. Adjusted non-parsimonious binary logistic regression models were fitted to estimate risks of primary and secondary endpoints by beta-blocker subgroups, in the overall population as well as clinically relevant subgroups previously defined. All regression analyses were adjusted for all variables mentioned in Table 1 . All models were tested for goodness of fit using Pearson's v 2 test and found valid.
Raw data was made anonymous with respect to name and address, and the unique social security number used for cross-linking data was only made available after centralized encryption. Furthermore, current rules dictate that any group or strata with counts less than 3 must be substituted with '<3' and the percentage with 'na' to ensure that no patient can be identified by the combination of time-period, demographic, and clinical variables. We tested whether our main findings differed by clinically relevant subgroups including gender, age < _75 vs. >75 years, diabetes, surgery priority, duration of anaesthesia < _120 vs. >120 min and surgery risk as low, intermediate and high risk.
Among patients initiating treatment within 120 days of surgery (having claimed just one prescription), risks of adverse events associated with treatment duration prior to surgery (1-120 days) were estimated using restricted cubic spline regression models adjusted for sex, age, surgery risk, and surgery priority. In a separate sensitivity analyses we excluded patients with treatment duration < _14 days.
For patients treated with metoprolol, we estimated beta blocker dose prior to surgery. The method used for dose calculation has been described in detail elsewhere. 23 Risks of adverse events associated with beta blocker dosages were estimated using restricted cubic spline regression models adjusted for sex, age, surgery risk, and surgery priority. This was done for three groups: all patients, patients with prior MI, and patients with heart failure. A two-sided P-value of <0.05 was considered statistically significant. All calculations were performed with SAS statistical software v. 9.4 
Outcomes
Thirty-day risks of all-cause mortality and MACE associated with beta-blocker subtypes are presented in Figure 2 . Patients treated with carvedilol had the highest unadjusted absolute risks of both all-cause mortality (4.80%) and MACE (4.56%) while patients treated with 'other' beta-blockers had the lowest absolute risks (2.34 and 1.73%, respectively). Fully adjusted logistic regression models showed that, compared with patients treated with metoprolol, all beta-blocker subtypes were associated with comparable risks of all-cause mortality and MACE ( Figure 2) . The individual components of MACE were studied as secondary outcomes. Risks of non-fatal MI (OR, 1.32 Figure S1 .
Subgroup characteristics and outcomes
Baseline characteristics for patients with heart failure, prior MI, diabetes, or uncomplicated hypertension are shown in Supplementary material online, Table S4A-D. Metoprolol was by far the most used beta-blocker in all subgroups (63.2-76.5%), while carvedilol was frequently used in patients with heart failure (18.1%) and atenolol frequently used in patients with uncomplicated hypertension (17.2%). Risks of all-cause mortality did not differ by beta-blocker subtype in any of the subgroups, with the exception that patients with prior MI were at significantly lower risks of all-cause mortality when treated with carvedilol (OR, 0.62; 95% CI, 0.43-0.87), compared with metoprolol, see Figure 3 . Analyses for the risk of MACE in patient subgroups did not yield any significant results for any subgroup, although trends toward increased risk with atenolol in patients with congestive heart failure (OR, 1.38 ; 95% CI, 0.995-1.90) or prior MI (OR, 1.97 ; 95% CI, 0.996-3.91) were observed (all results are presented in Supplementary material online, Figure S2) 
Interaction analyses
Risks of all-cause mortality associated with beta-blocker subtype did not differ by age, diabetes, surgery priority, duration of anaesthesia or surgery risk (all P for interaction >0.05). Male patients were at increased risks of all-cause mortality compared with female patients, when treated with beta-blockers other than metoprolol (P for interaction 0.048). All analyses are presented in Supplementary material online, Table S5 .
Exploratory analyses
Treatment duration with metoprolol or beta-blockers other than metoprolol prior to surgery (1-120 days) was estimated for a subset of the population claiming just one prescription prior to surgery (n = 4207, 6.8%). Adjusted spline regression analyses showed that treatment duration was not associated with risks of 30-day MACE (P for non-linearity was 0.848 and 0.755, respectively) or mortality (P for non-linearity was 0.827 and 0.756, respectively) (Supplementary material online, Figure S3 ). In adjusted logistic regression analyses we excluded patients with treatment duration < _14 days (n = 572), which did not change the estimates compared with our main analyses (Supplementary material online, Figure S4 ).
For patients treated with metoprolol we estimated daily dose to range between 12.5 and 400 mg. In adjusted spline regression analyses we found that, compared with the reference dose of 50 mg, lower or higher doses was not significantly associated with risks of MACE or mortality (all P for non-linearity >0.05) (Supplementary material online, Figure S5) Defined as time between first-ever claimed beta-blocker prescription and date of surgery. Multivariable analyses were not adjusted for treatment duration.
Figure 2
Risks of 30-day all-cause mortality and MACE in the overall population. MACE, major adverse cardiovascular events, included non-fatal ischaemic stroke, non-fatal MI and cardiovascular death. 'Other' included the beta-blockers acebutolol, nebivolol, pindolol, and labetalol. All analyses were adjusted for gender, age, body mass index, comorbidities, pharmacotherapy, surgery subtype, surgery priority, and surgery risk, as listed in Table 1 . 
Discussion
In a large and representative cohort, the most common beta-blocker subtypes used for chronic treatment were associated with similar risks of perioperative mortality, cardiovascular death, and stroke following non-cardiac surgery. Subgroups of patients defined by the presence of heart failure, prior MI, diabetes or uncomplicated hypertension did not show statistically significant associations between beta-blocker subtypes and risks of adverse events. Further analyses showed that the main findings of a non-statistically significant association between beta blocker subtype and adverse events remained so in strata of age, surgery priority, surgery risk, and duration of anaesthesia. Our observations therefore suggest similar perioperative outcomes for the most commonly used types of beta-blockers in patients undergoing non-cardiac surgery.
Previous studies, non-surgical and surgical
Trials including low-and/or high-risk patients, undergoing either general or vascular surgery, have previously evaluated several betablocker subtypes for their ability to reduce perioperative morbidity and mortality. [6] [7] [8] [9] [10] [11] [12] [13] In some trials, the choice of study drug was based on concerns regarding varying half-life 9 , consistency in effect on heart rate 12 , and genetic polymorphisms influencing stereoselective metabolism (such as metoprolol and carvedilol but not bisoprolol). 8, 24 For instance, metoprolol is extensively metabolized by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6), and patients' genetic variants of this enzyme could affect subsequent risks of perioperative adverse events, although the chronic use of beta blocker in this study may be less susceptible to such variations due to possible titration. 25 Such biological interactions illustrate the complexity of choosing a beta-blocker in clinic and underlines the importance of careful planning when designing clinical trials evaluating beta-blocker safety and efficacy in the perioperative setting. This observational study did not demonstrate an association between beta-blocker subtype and perioperative mortality, however, due to our study design, we cannot exclude the possibility that a more granular stratification by genetic polymorphisms and/or refined clinical variables including echocardiography, blood pressure values, pulse, and cardiopulmonary fitness would yield different results. Future studies assessing the effect of beta-blockers for perioperative adverse events should take these possibilities into account. Beta-blocker treatment duration prior to surgery have been discussed in recent guidelines, 22 suggesting that high-dose beta-blocker initiation without sufficient time for titration prior to surgery may be harmful. In subgroups of patients initiating beta blocker within 1-120 days of surgery we were not able to demonstrate an association between treatment duration and risks of adverse events. Similarly, in exploratory analyses, beta-blocker daily-dose was not associated with perioperative adverse events. However, as information on administration and changes in in-hospital drugs was not available, and due to the lack of variables describing disease severity, our study design remains sub-optimal for addressing these questions. In a review of randomized trials, Auerbach and colleagues concluded that Figure 3 Risks of 30-day all-cause mortality by subgroups. 'Other' included the beta-blockers acebutolol, nebivolol, pindolol, and labetalol. All analyses were adjusted for gender, age, body mass index, surgery priority, comorbidities, pharmacotherapy, surgery subtype and surgery risk, as listed in Table 1 . As the number of events in patients treated with 'other' beta-blockers in patients with prior myocardial infarction were <3, these estimates were left out to comply with current rules for non-identifiable data.
there was no evidence to support the use of a specific beta-blocker subtype and that physicians should keep in mind that discontinuing or replacing a beta-blocker may itself be directly associated with increased perioperative risks, 26, 27 Summarizing prior studies, it has been suggested that rates of perioperative outcomes were lower with atenolol, intermediate with bisoprolol, and higher with metoprolol, but these were not head-to-head comparisons and the studies evaluated short-term beta blocker exposure. 28 Careful perioperative evaluation of the individual patient remains important.
Limitations
Our study population was a nationwide contemporary and representative cohort of patients treated with beta-blockers, as clinicians would encounter in everyday practice. Since healthcare services are equally available to all permanent residents, social disparities related to healthcare availability were not a major issue of our study. Furthermore, tracking individuals by their unique social security number ensured high data accuracy and complete follow-up data. The specific combination of race, age, medical conditions etc. in our study population may differ from that of other populations, thus limiting the generalizability of our findings. No information on race was available, but the Danish population is predominantly white, and the results should be interpreted with this in mind. Less than 5% of the surgeries were high-risk thus limiting the power of the analysis for this important subgroup.
The indication for beta-blocker treatment was unknown and the current stratification by beta-blocker subtype in clinically relevant subgroups may not be sensitive to capture true differences with betablocker treatment in subgroups. No information was available on intra-and post-operative heart rate, blood pressure measurements, need for inotropic therapy, or fluid administration. These factors could potentially confound our estimates, as a capable anaesthesiologist may be able to effectively treat negative symptoms associated with betablocker treatment during the intense perioperative monitoring. Also, data on biochemistry and biomarkers for blood glucose, inflammatory markers, coagulation status, electrolytes, or brain natriuretic peptide as well as echocardiography, electrocardiograms, chest X-ray, and pulmonary function tests were not available, and we acknowledge that any of these could serve as an unmeasured confounder and that there may be residual confounding. Metoprolol succinate and tartate could not be examined individually due to identical ATC codes. In-hospital initiation, changes, or discontinuation of the beta-blocker treatment were unknown but given that beta-blocker withdrawal is inadvisable this may not be an important confounder.
Conclusions
Due to the complex pharmacodynamics and pharmacokinetics of the diverse group of beta-blockers available to clinicians, it was hypothesized that risks of perioperative adverse outcomes following non-cardiac surgery might vary with beta-blocker subtypes. After full adjustment for differences in baseline characteristics, risks of mortality and cardiovascular adverse events did not differ by beta-blocker subtype in the main cohort or in subgroups of patients with heart failure, prior MI, diabetes or uncomplicated hypertension. Based on our findings, we conclude that the choice of a specific beta-blocker subtype does not seem to affect the risks of adverse events in patients undergoing non-cardiac surgery.
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